- Home
- UOKA vs EYEN Comparison
UOKA vs EYEN Comparison
Compare UOKA & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UOKA
- EYEN
- Stock Information
- Founded
- UOKA 2002
- EYEN 2014
- Country
- UOKA United Kingdom
- EYEN United States
- Employees
- UOKA N/A
- EYEN N/A
- Industry
- UOKA
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- UOKA
- EYEN Health Care
- Exchange
- UOKA NYSE
- EYEN Nasdaq
- Market Cap
- UOKA 2.7M
- EYEN 2.9M
- IPO Year
- UOKA N/A
- EYEN 2018
- Fundamental
- Price
- UOKA $2.40
- EYEN $11.93
- Analyst Decision
- UOKA
- EYEN Hold
- Analyst Count
- UOKA 0
- EYEN 4
- Target Price
- UOKA N/A
- EYEN $2.00
- AVG Volume (30 Days)
- UOKA 128.0K
- EYEN 9.8M
- Earning Date
- UOKA 08-16-2025
- EYEN 08-11-2025
- Dividend Yield
- UOKA N/A
- EYEN N/A
- EPS Growth
- UOKA N/A
- EYEN N/A
- EPS
- UOKA N/A
- EYEN N/A
- Revenue
- UOKA $48,375.00
- EYEN $67,063.00
- Revenue This Year
- UOKA N/A
- EYEN $7,680.45
- Revenue Next Year
- UOKA N/A
- EYEN $315.38
- P/E Ratio
- UOKA N/A
- EYEN N/A
- Revenue Growth
- UOKA N/A
- EYEN 663.82
- 52 Week Low
- UOKA $1.98
- EYEN $0.85
- 52 Week High
- UOKA $42.50
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- UOKA N/A
- EYEN 69.20
- Support Level
- UOKA N/A
- EYEN $3.68
- Resistance Level
- UOKA N/A
- EYEN $11.40
- Average True Range (ATR)
- UOKA 0.00
- EYEN 2.03
- MACD
- UOKA 0.00
- EYEN 0.58
- Stochastic Oscillator
- UOKA 0.00
- EYEN 73.25
About UOKA MDJM LTD
MDJM Ltd is engaged in providing real estate agency services to its real estate developer clients, and provides, on an as-needed basis, real estate consulting services and independent training services. The company generates all of its revenue from Hotel income. The company derives a majority of its revenue from the United Kingdom.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.